Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells | BioMed Central Journal of Hematology Oncology Research Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells Che K Lim1 Li Sun1 Qi Feng2 6 Ping Law3 Wei T Chua4 Shy N Lim4 and William YK Hwang 2 5 6 Address Department of Clinical Research Singapore General Hospital Outram Road Singapore 2Department of Hematology Singapore General Hospital Outram Road Singapore 3Stemcyte Covina CA USA 4Nanyang Technological University 50 Nanyang Avenue Singapore 5Duke- NUS Graduate Medical School Singapore Jalan Bukit Merah Singapore and Singapore Cord Blood Bank 100 Bukit Timah Road Singapore Email Che K Lim - Li Sun - Qi Feng - Ping Law - pinglaw@ Wei T Chua - chuaweiting@ ShyN Lim-shineni@ William YK Hwang - Corresponding author Open Access Published 23 October 2008 Received 10 August 2008 Journal of Hematology Oncology 2008 1 19 doi l756-8722-l-l9 Accepted 23 October 2008 This article is available from http content l l l9 2008 Lim et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract_ Background Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood CB expansion. In this study we report the effects of anit-CD52 Alemtuzumab Campath on both short- and long-term ex vivo expansion of CB hematopoietic stem cells HSC by evaluating the potential role of Alemtuzumab in preserving the repopulating capability in CB HSC and nonlymphoid progenitors. Methods Ex vivo expansion experiments were carried out using .
